A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Hookworm (Ancylostoma Duodenale and Necator Americanus), Ascaris Lumbricoides, and Trichuris Trichiura in Pediatric and Adult Participants

Zero Point Five Therapeutics1 site in 1 country300 target enrollmentFebruary 14, 2025

ConditionsSoil-Transmitted Helminthiasis (STH)

InterventionsZP5-9676 600 mg dose Placebo

DrugsZP5-9676 600 mg dose Placebo

Overview

Phase: Phase 3
Intervention: ZP5-9676 600 mg dose
Conditions: Soil-Transmitted Helminthiasis (STH)
Sponsor: Zero Point Five Therapeutics
Enrollment: 300
Locations: 1
Primary Endpoint: Cure rates
Status: Recruiting
Last Updated: 7 months ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a Phase 3, multi-center, prospective, randomized, double-blind, placebo-controlled study to evaluate the effectiveness, safety, and tolerability of ZP5-9676 compared to placebo for the treatment of STH infections. Approximately 300 participants will be enrolled, randomized at the Baseline visit (Day 1) to one of the following treatments in a 1:1 ratio of active and placebo.

Detailed Description

Approximately 300 infected participants will be enrolled to ensure that there is a minimum of 114 hookworm-infected participants evaluable for the Test of Cure study visit (Day 14). Some participants may be co-infected and will be included in each tally. Participants will be randomized (1:1) to one of the treatments below followed by standard of care treatment: * Treatment A: ZP5-9676 600 mg dose * Treatment B: Placebo

Registry

clinicaltrials.gov

Start Date

February 14, 2025

End Date

December 31, 2026

Last Updated

7 months ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Zero Point Five Therapeutics

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Provide a signed informed consent form from the participant or parent/guardian, and assent by participant(as applicable per local requirements) and understand and agree to comply with required procedures in the study.
•Male or female, who are 6 months to 59 years old, inclusive, and live in a high STH prevalence area
•Positive for hookworm (A. duodenale or N. americanus), A. lumbricoides, and/or T. trichiura on microscopic examination of fecal samples.
•Females of childbearing potential must use an acceptable method of contraception as determined by the Investigator from the initial Screening visit through 35 days after study drug administration. A female is considered to be of childbearing potential from menarche until after menopause (age \>45 years with no menses for 12 months without an alternative medical cause) unless permanently sterile. Acceptable methods include abstinence, hormonal contraceptives, intrauterine device/system, vasectomy in the sole male sexual partner, tubal ligation, or double-barrier contraceptive method (male condom with female cervical cap, diaphragm, or sponge) with spermicide.
•Otherwise healthy based on medical history, physical examination, vital signs, and concomitant medications for inclusion.

Exclusion Criteria

•Severe anemia (hemoglobin\< 8 g/dL1).
•Active diarrhea (passage of ≥3 loose or liquid stools per day).
•Children (6 months to 17 years old) with significant wasting (moderate and severe-below minus two standard deviations from median weight for height of reference population).
•Women who are pregnant.
•Hypersensitivity or allergy to ZP5-9676 or any inert ingredients in the chewable formulation or other medications in the benzimidazole class.
•Taken ZP5-9676 or any other treatment for STH infection within 30 days of screening or randomization.
•Used an investigational medical device within 30 days of screening.
•Preplanned surgery procedures within 30 days of screening.
•History of a medical disorder causing difficulty in chewing or swallowing.
•Participation in any investigational drug (including vaccine) trial within 30 days or six half-lives of the test drug's biologic activity, whichever is longer, before the start of the study (time of first dose).